Effect of deferiprone or deferoxamine on right ventricular function in thalassemia major patients with myocardial iron overload

Journal of Cardiovascular Magnetic Resonance

Volumn 13, Issue 1, 2011, Pages

  Smith, Gillian C ^a,b   Alpendurada, Francisco ^a   Carpenter, John Paul ^a,b   Alam, Mohammed H ^a,b   Berdoukas, Vasili ^c   Karagiorga, Markissia ^d   Ladis, Vasili ^d   Piga, Antonio ^e   Aessopos, Athanassios ^f   Gotsis, Efstathios D ^g   Tanner, Mark A ^h   Westwood, Mark A ⁱ   Galanello, Renzo ^j   Roughton, Michael ^k   Pennell, Dudley J ^a,b  

^a ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^g Institute Euromedica Encephalos   (Greece)

^h ST RICHARD S HOSPITAL   (United Kingdom)

ⁱ LONDON CHEST HOSPITAL   (United Kingdom)

^j UNIVERSITY OF CAGLIARI   (Italy)

^k UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DEFERIPRONE; DEFEROXAMINE; IRON CHELATING AGENT; PYRIDONE DERIVATIVE; SIDEROPHORE;

ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE ENDSYSTOLIC VOLUME; HEART RIGHT VENTRICLE FUNCTION; HUMAN; IRON OVERLOAD; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; THALASSEMIA MAJOR; ADULT; ANALYSIS OF VARIANCE; BETA THALASSEMIA; BLOOD; BLOOD TRANSFUSION; CARDIOMYOPATHY; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; GREECE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; HEART STROKE VOLUME; ITALY; MALE; METABOLISM; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME;

ADULT; ANALYSIS OF VARIANCE; BETA-THALASSEMIA; BLOOD TRANSFUSION; CARDIOMYOPATHIES; DEFEROXAMINE; FEMALE; GREECE; HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; ITALY; MAGNETIC RESONANCE IMAGING; MALE; MULTICENTER STUDIES AS TOPIC; MYOCARDIUM; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; SIDEROPHORES; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR FUNCTION, RIGHT; YOUNG ADULT;

EID: 80053488289     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/1532-429X-13-34     Document Type: Article

References (37)

1. Survival in medically treated patients with homozygous beta thalassaemia. Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR, N Engl J Med 1994 331 574 8 10.1056/NEJM199409013310903 8047081 (Pubitemid 24265699)
2. Survival in beta thalassaemia major in the UK: Data from the UK Thalassaemia Register. Modell B, Khan M, Darlison M, Lancet 2000 355 2051 2 10.1016/S0140-6736(00)02357-6 10885361 (Pubitemid 30339248)
3. Role of iron in inducing oxidative stress in thalassemia: Can it be prevented by inhibition of absorption and by antioxidants? Rachmilewitz EA, Weizer-Stern O, Adamsky K, Amariglio N, Rechavi G, Breda L, Rivella S, Cabantchik ZI, Ann N Y Acad Sci 2005 1054 118 23 10.1196/annals.1345.014 16339657 (Pubitemid 43031016)
4. The importance of non-transferrin bound iron in disorders of iron metabolism. Breuer W, Hershko C, Cabantchik ZI, Transfus Sci 2000 3 185 92
5. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ, Eur Heart J 2001 22 2171 9 10.1053/euhj.2001.2822 11913479 (Pubitemid 33139463)
6. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Wood JC, Otto-Duessel M, Aguilar M, Nick H, Nelson MD, Coates TD, Pollack H, Moats R, Circulation 2005 112 535 43 10.1161/ CIRCULATIONAHA.104.504415 16027257 (Pubitemid 41060794)
7. Thalassemia. Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E, Hematology Am Soc Hematol Educ Program 2004 14 34
8. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, Wu D, Taylor J, Westwood MA, Anderson LJ, Pennell DJ, Circulation 2009 120 1961 8 10.1161/CIRCULATIONAHA.109.874487 19801505
9. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ, J Cardiovasc Magn Reson 2008 10 42 10.1186/1532-429X-10-42 18817553
10. Practical management of iron overload. Porter JB, Br J Haematol 2001 115 239 52 10.1046/j.1365-2141.2001.03195.x 11703317 (Pubitemid 34203484)
11. Secondary iron overload. Kushner JP, Porter JP, Olivieri NF, Hematology 2001 47 61
12. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, Nair SV, Anderson LJ, Walker JM, Pennell DJ, J Cardiovasc Magn Reson 2006 8 543 7 10.1080/10976640600698155 16755844
13. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ, Eur Heart J 2001 22 2171 9 10.1053/euhj.2001.2822 11913479 (Pubitemid 33139463)
14. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R, Blood 2006 107 3738 44 10.1182/blood-2005-07-2948 16352815
15. Additional predictive value of both left and right ventricular ejection fractions on long-term survival in idiopathic dilated cardiomyopathy. Juillière Y, Barbier G, Feldmann L, Grentzinger A, Danchin N, Cherrier F, Eur Heart J 1997 18 276 80 9043845 (Pubitemid 27107590)
16. Right ventricular ejection fraction is an independent predictor of survival in patients with moderate heart failure. de Groote P, Millaire A, Foucher-Hossein C, Nugue O, Marchandise X, Ducloux G, Lablanche JM, J Am Coll Cardiol 1998 32 948 54 10.1016/S0735-1097(98)00337-4 9768716 (Pubitemid 28459583)
17. Right ventricular dysfunction assessed by cardiovascular magnetic resonance imaging predicts poor prognosis late after myocardial infarction. Larose E, Ganz P, Reynolds HG, Dorbala S, Di Carli MF, Brown KA, Kwong RY, J Am Coll Cardiol 2007 49 855 62 10.1016/j.jacc.2006.10.056 17320743
18. Extent of RV dysfunction and myocardial infarction assessed by CMR are independent outcome predictors early after STEMI treated with primary angioplasty. Miszalski-Jamka T, Klimeczek P, Tomala M, Krupiski M, Zawadowski G, Noelting J, Lada M, Sip K, Bany R, Mazur W, Kereiakes DJ, Zmudka K, Pasowicz M, JACC Cardiovasc Imaging 2010 12 1237 46
19. Right ventricular volumes and function in thalassemia major patients in the absence of myocardial iron overload. Carpenter JP, Alpendurada F, Deac M, Maceira A, Garbowski M, Kirk P, Walker JM, Porter JB, Shah F, Banya W, He T, Smith GC, Pennell DJ, J Cardiovasc Magn Reson 2010 12 24 10.1186/1532-429X-12-24 20416084
20. Relation of myocardial T2* to right ventricular function in thalassaemia major. Alpendurada F, Carpenter JP, Deac M, Kirk P, Walker JM, Porter JB, Banya W, He T, Smith GC, Pennell DJ, Eur Heart J 2010 31 1648 54 10.1093/eurheartj/ehq106 20413399
21. Normal human right and left ventricular mass, systolic function and gender differences by cine magnetic resonance imaging. Lorenz CH, Walker ES, Morgan VL, Klein SS, Graham TP, J Cardiovasc Magn Reson 1999 1 7 21 10.3109/10976649909080829 11550343
22. Normal human left and right ventricular and left atrial dimensions using steady state free precession magnetic resonance imaging. Hudsmith LE, Petersen SE, Francis JM, Robson MD, Neubauer SJ, J Cardiovasc Magn Reson 2005 7 775 82 10.1080/10976640500295516 16353438 (Pubitemid 41770055)
23. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Grothues F, Smith GC, Moon JC, Bellenger NG, Collins P, Klein HU, Pennell DJ, Am J Cardiol 2002 90 29 34 10.1016/S0002-9149(02)02381-0 12088775 (Pubitemid 34671198)
24. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Grothues F, Moon JC, Bellenger NG, Smith GS, Klein HU, Pennell DJ, Am Heart J 2004 147 218 33 10.1016/j.ahj.2003. 10.005 14760316 (Pubitemid 38176819)
25. Decline in ventricular function and clinical condition after Mustard repair for transposition of the great arteries (a prospective study of 22-29 years). Roos-Hesselink JW, Meijboom FJ, Spitaels SE, van Domburg R, van Rijen EH, Utens EM, McGhie J, Bos E, Bogers AJ, Simoons ML, Eur Heart J 2004 25 1264 70 10.1016/j.ehj.2004.03.009 15246646 (Pubitemid 38891578)
26. Long-term outcome in congenitally corrected transposition of the great arteries: a multi-institutional study. Graham TP Jr, Bernard YD, Mellen BG, Celermajer D, Baumgartner H, Cetta F, Connolly HM, Davidson WR, Dellborg M, Foster E, Gersony WM, Gessner IH, Hurwitz RA, Kaemmerer H, Kugler JD, Murphy DJ, Noonan JA, Morris C, Perloff JK, Sanders SP, Sutherland JL, J Am Coll Cardiol 2000 36 255 61 10.1016/S0735-1097(00)00682-3 10898443 (Pubitemid 30466142)
27. Right ventricular diastolic function 15 to 35 years after repair of tetralogy of Fallot. Restrictive physiology predicts superior exercise performance. Gatzoulis MA, Clark AL, Cullen S, Newman CG, Redington AN, Circulation 1995 91 1775 81 7882487
28. Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure. Meyer P, Filippatos GS, Ahmed MI, Iskandrian AE, Bittner V, Gilbert J, Perry GJ, White M, Aban IB, Mujib M, Dell'Italia LJ, Ahmed A, Circulation 2010 121 252 8 10.1161/CIRCULATIONAHA.109.887570 20048206
29. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. Di Salvo TG, Mathier M, Semigran MJ, Dec GW, J Am Coll Cardiol 1995 25 1143 53 10.1016/0735-1097(94)00511-N 7897128
30. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustini E, Recusani F, Tavazzi L, J Am Coll Cardiol 2001 37 183 8 10.1016/S0735-1097(00) 01102-5 11153735 (Pubitemid 32051736)
31. Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. Kakhlon O, Manning H, Breuer W, Melamed-Book N, Lu C, Cortopassi G, Munnich A, Cabantchik ZI, Blood 2008 112 5219 27 10.1182/blood-2008-06-161919 18796625
32. Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions. Kontoghiorghes GJ, Efstathiou A, Kleanthous M, Michaelides Y, Kolnagou A, Hemoglobin 2009 33 386 97 10.3109/03630260903217141 19814684
33. Improvement in right ventricular function following 1 year of deferasirox therapy in patients with -thalassemia. Smith G, Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy M, Kattamis A, Habr D, Domokos G, Hmissi A, Taher A, Blood 2009 114 bstract 5106
34. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, Elalfy MS, Sutcharitchan P, Li CK, Ibrahim H, Viprakasit V, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A, Blood 2010 115 2364 71 10.1182/blood-2009-04-217455 19996412
35. Continued improvement in myocardial T2* over 2 years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A, Haematologica 2011 96 48 54 10.3324/haematol.2010.031468 21071497
36. Continued improvement and normalization of myocardial T2* in patients with thalassemia major treated with Deferasirox (Exjade) for up to 3 years. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A, Blood 2010 116 bstract 4276
37. Cardiac status in well treated patients with thalassemia major. Aessopos A, Farmakis D, Hatziliami A, Fragodimitri C, Karabatsos F, Joussef J, Mitilineou E, Diamanti-Kandaraki E, Meletis J, Karagiorga M, Eur J Haematol 2004 73 359 66 10.1111/j.1600-0609.2004.00304.x 15458515 (Pubitemid 39349917)